Patents by Inventor Peng Cho Tang

Peng Cho Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
    Patent number: 6329375
    Abstract: The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: December 11, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Bicyclic protein kinase inhibitors
    Patent number: 6316429
    Abstract: The present invention relates to novel 3-idene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 2-indolinone derivatives as modulators of protein kinase activity
    Patent number: 6316635
    Abstract: The present invention relates to novel imidazoly 2-indolinones and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, G. David Harris
  • Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
    Patent number: 6316479
    Abstract: The present invention relates to novel isoxazole-4-carboxamides which modulate the activity of protein tyrosine kinases and therefore are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders including cancer.
    Type: Grant
    Filed: May 19, 1998
    Date of Patent: November 13, 2001
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Peng Cho Tang, Laura Kay Shawver, Klaus Peter Hirth
  • Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
    Patent number: 6313158
    Abstract: The present invention relates to novel 3-heteroarylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which have improved hydrosolubility and which are expected to modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: November 6, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Publication number: 20010027207
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: January 22, 2001
    Publication date: October 4, 2001
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Novel 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
    Publication number: 20010007033
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to e useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Application
    Filed: March 1, 2000
    Publication date: July 5, 2001
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Patent number: 6239161
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2-and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: May 29, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • Tyrphostin like compounds
    Patent number: 6225346
    Abstract: The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 1, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Asaad S. Nematalla, Gerald McMahon
  • 3-(4?-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
    Patent number: 6225335
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: May 1, 2001
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Indolinone combinatorial libraries and related products and methods for the treatment of disease
    Patent number: 6147106
    Abstract: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1' position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: November 14, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Klaus Peter Hirth, Laura Kay Shawver
  • Pharmaceutical compositions and methods for modulating signal transduction
    Patent number: 6143765
    Abstract: The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: November 7, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
    Patent number: 6133305
    Abstract: The present invention relates to novel 3-(substituted)-2-indolinones compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related disorders such as cancer.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: October 17, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6130238
    Abstract: The present invention relates to novel 3-(cyclohexanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 10, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    Patent number: 6114371
    Abstract: The present invention relates to novel 3-(cyclohexano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: September 5, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon, Robert A. Blake
  • Quinazolines
    Patent number: 6103728
    Abstract: Molecules that are capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities. These compounds have the structural formula ##STR1## wherein R1-R10 are disclosed in the specification. The specification also provides pharmaceutical compositions and methods for inhibiting cell proliferation or differentiation and related disorders.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: August 15, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon
  • Methods and compositions for inhibition of adaptor protein/tyrosine kinase interactions
    Patent number: 6090838
    Abstract: The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: July 18, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris
  • Thiazole compounds and methods of modulating signal transduction
    Patent number: 6080772
    Abstract: The present invention relates to thiazole containing compounds capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such compounds to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such compounds to treat various disease states including diabetes mellitus.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: June 27, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, John Yudhistir Ramphal, G. Davis Harris, Jr., Asaad S. Nematalla
  • 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
    Patent number: 6051593
    Abstract: The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: April 18, 2000
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Li Sun, Gerald McMahon
  • Psoriasis treatment with quinazoline compounds
    Patent number: 6004967
    Abstract: This invention is directed to methods and compositions for treating hyperproliferative skin disorders utilizing a quinazoline derivative as an active ingredient.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: December 21, 1999
    Assignee: Sugen, Inc.
    Inventors: Gerald McMahon, Laura Shawver, Blair Narog, Peng Cho Tang, Klaus Peter Hirth